Compare Glenmark Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BIOCON - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BIOCON GLENMARK PHARMA/
BIOCON
 
P/E (TTM) x 12.2 17.1 71.2% View Chart
P/BV x 1.7 2.6 65.8% View Chart
Dividend Yield % 0.6 0.4 127.1%  

Financials

 GLENMARK PHARMA   BIOCON
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
BIOCON
Mar-18
GLENMARK PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs7121,188 59.9%   
Low Rs484305 158.6%   
Sales per share (Unadj.) Rs349.668.7 508.7%  
Earnings per share (Unadj.) Rs32.87.6 434.1%  
Cash flow per share (Unadj.) Rs44.314.0 317.3%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.1 249.8%  
Book value per share (Unadj.) Rs198.686.3 230.1%  
Shares outstanding (eoy) m282.17600.00 47.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.710.9 15.7%   
Avg P/E ratio x18.298.9 18.4%  
P/CF ratio (eoy) x13.553.4 25.2%  
Price / Book Value ratio x3.08.6 34.8%  
Dividend payout %6.113.2 46.1%   
Avg Mkt Cap Rs m168,625447,900 37.6%   
No. of employees `00012.06.1 195.8%   
Total wages/salary Rs m20,5619,311 220.8%   
Avg. sales/employee Rs Th8,196.06,705.8 122.2%   
Avg. wages/employee Rs Th1,708.11,514.2 112.8%   
Avg. net profit/employee Rs Th768.5736.9 104.3%   
INCOME DATA
Net Sales Rs m98,65541,234 239.3%  
Other income Rs m2,0812,062 100.9%   
Total revenues Rs m100,73643,296 232.7%   
Gross profit Rs m15,8588,291 191.3%  
Depreciation Rs m3,2593,851 84.6%   
Interest Rs m3,346615 544.0%   
Profit before tax Rs m11,3355,887 192.5%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7561,569 239.4%   
Profit after tax Rs m9,2504,531 204.1%  
Gross profit margin %16.120.1 79.9%  
Effective tax rate %33.126.7 124.3%   
Net profit margin %9.411.0 85.3%  
BALANCE SHEET DATA
Current assets Rs m66,96841,486 161.4%   
Current liabilities Rs m40,21121,413 187.8%   
Net working cap to sales %27.148.7 55.7%  
Current ratio x1.71.9 86.0%  
Inventory Days Days8364 130.3%  
Debtors Days Days8194 86.2%  
Net fixed assets Rs m33,32250,661 65.8%   
Share capital Rs m2823,000 9.4%   
"Free" reserves Rs m55,77048,808 114.3%   
Net worth Rs m56,05251,808 108.2%   
Long term debt Rs m35,73817,898 199.7%   
Total assets Rs m132,88899,897 133.0%  
Interest coverage x4.410.6 41.5%   
Debt to equity ratio x0.60.3 184.6%  
Sales to assets ratio x0.70.4 179.9%   
Return on assets %9.55.2 184.0%  
Return on equity %16.58.7 188.7%  
Return on capital %17.89.6 184.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99812,058 522.5%   
Fx outflow Rs m22,8597,348 311.1%   
Net fx Rs m40,1404,710 852.2%   
CASH FLOW
From Operations Rs m13,2426,621 200.0%  
From Investments Rs m-6,990-6,840 102.2%  
From Financial Activity Rs m-7,387-2,397 308.2%  
Net Cashflow Rs m-2,971-2,612 113.7%  

Share Holding

Indian Promoters % 48.3 40.4 119.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 6.9 8.4 82.1%  
FIIs % 34.4 10.7 321.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   56,727 109,995 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Metal and Banking Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 1.1%.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 19, 2019 11:39 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DR. REDDYS LAB COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS